News Sort by Year All Years 2024 (12) 2023 (28) 2022 (31) 2021 (33) 2020 (37) 2019 (7) 2018 (4) Search May 1, 2024 TFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public Offering April 29, 2024 TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual Meeting April 29, 2024 TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering April 15, 2024 TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessions March 28, 2024 TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results March 27, 2024 TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs March 25, 2024 TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting March 22, 2024 TFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules March 20, 2024 TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules March 20, 2024 TFF Pharmaceuticals Announces Update on Clinical Programs